Skip to main content
OpenTrials
Completed

NCT Number: NCT03458650

A Phase I Study of LuoXin Innovate (LXI-15028) in Healthy Chinese Subjects to Evaluate the Pharmacokinetics, Safety and Tolerability.

"This study is a single-center, randomized, double-blinded and placebo-controlled trial designed not only to assess pharmacokinetics, safety and tolerability of LXI-15028 but also to evaluate the pharmacokinetic characteristics of main metabolite M1 in vivo in 38 healthy adult Chinese subjects after receiving escalating single oral doses of 50 mg, 100 mg and 200 mg and multiple oral doses of 100 mg of LXI-15028.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Huashan Hospital, Fudan University

Shanghai, Shanghai Municipality, 200040, China

About this study

This study includes 3 dose groups which are 50 mg (Group 1), 100 mg(Group 2) and 200 mg(Group 3) respectively. For 50 mg and 200 mg dose groups, each is planned to enroll 12 healthy subjects (investigational drug :placebo=10:2), half males and half females. Five subjects of each gender will receive LXI-15028, while 1 subject of each gender will receive placebo; 100 mg dose group plans to enroll 14 healthy subjects (investigational drug:placebo=10:4), half males and half females. Five subjects of each gender will receive LXI-15028, while 2 subjects of each gender will receive placebo. Intra-group randomization will be implemented in each dose group; each subject will receive either LXI-15028 or placebo.

This study includes 2 parts of single-dose and multiple-dose administration. The single-dose study will use gradually escalation dosing to evaluate the 3 doses of 50 mg, 100 mg and 200 mg. Within 4 days after each dose is administered, the investigators will assess the safety and tolerability data to decide whether to proceed with the next escalated single dose. Within 4 days of 200 mg single-dose administration, the investigators will assess the safety and tolerability data to decide whether to proceed with 100 mg multiple-dose study. Multiple-dose study will be investigated in 100 mg group only.

The study consists of screening period, treatment period and follow-up in each dose group. The treatment period in 50 mg and 200 mg dose groups include single-dose administration only. While the treatment period in 100 mg dose group includes both single-dose and multiple-dose administration. The subjects in 100 mg dose group will enter multiple-dose period following completing single-dose period.

In escalated single-dose study, the subjects in each dose group will receive single oral dose of 50 mg LXI-15028 tablet or 1 matching placebo tablet at fasted state, or 100 mg LXI-15028 tablet or matching placebo 1 tablet, or 2 100 mg LXI-15028 tablets or 2 matching placebo tablets. Blood samples will be collected before administration (0h), and 15 min (0.25h), 30 min (0.5h), 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 48h and 72h after administration. In multiple-dose study, the subjects will continuously receive oral 100 mg LXI-15028 tablet or 1 matching placebo tablet once daily (QD) for 10 times. Blood samples of trough concentration will be collected before the 8th to 10th administration (0h) in multiple-dose study. And blood samples will be collected at 15 min (0.25h), 30 min (0.5h), 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 48h and 72h after the 10th administration.

The collected blood samples will be processed to obtain plasma. Liquid Chromatographic(LC) /Mass Spectra(MS)/Mass Spectra (MS) method will be used to determine plasma concentrations of LXI-15028 and its major metabolite M1 in order to evaluate the pharmacokinetic characteristics of LXI-15028 and its metabolite M1 after oral administration of LXI-15028 tablet.

The safety will be assessed by physical examination, vital signs, ECG, laboratory examinations and adverse events in subjects receiving LXI-15028 tablet.

"

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The subjects should voluntarily participate in this trial and sign the informed consent form prior to conducting any trial-related procedures;
  • Gender: male or female healthy subjects; Age: 18~45 years old (including 18 and 45 years old);
  • The body weight should be equal or greater than 50.0 kg for male and 45.0 kg for female. Body weight index (BMI)= body weight (kg)/[height(m)×height(m)], should be within the range from 19 to 25 (including 19 and 25);
  • In the past three years, no history or presence of cardiovascular, hepatic, renal, respiratory, hematological and lymphatic, endocrine, immunological, mental, neurological and gastrointestinal disease; no history of surgery;
  • The subjects (including males and females) agree to use medically approved contraceptive methods during the trial period and within 3 months after the end of the trial in order to avoid pregnancy; medically approved contraceptive methods include intrauterine device, physical barrier (male condom, female condom), subcutaneous implant, sustained-release contraceptive, bilateral salpingectomy, bilateral tubal ligation, bilateral vas ligation, etc.;
  • The subjects agree not to donate sperms (males) or ova (females) at least 7 days before the first dose, during the study and within 3 months after ending of this study.

Exclusion criteria

  • The subjects with allergic constitution, for example those with bronchial asthma, allergic to food or pollen, allergic to two or more drugs or those with known history of allergy ; or the subjects with any serious adverse response to Proton Pump Inhibitor or P-CABs previously (e.g., omeprazole, rabeprazole, lansoprazole and TAK-481 ), or known allergy to penicillins or cephalosporins;
  • The investigator determines that it may potentially affect absorption, distribution, metabolism or elimination of investigational drug (e.g. organ dysfunction);
  • The subjects with a history of drug abuse or drug abuse screening positive;
  • The subjects received any drugs (including prescription drugs, Over-The-Counter drugs, herbal medicines, etc.) within 1 month before the screening or are taking drugs, especially CYP3A inhibitor or inducer (see Appendix 1);
  • The subjects with clinical significant physical examination abnormalities determined by investigator;
  • Heart rate<50 beats/min or >100 beats/min or QTc interval prolonged (male QTcF≥430ms, female QTcF≥450ms) or QRS≥120 msec or other clinically significant ECG abnormalities; 7) The subjects with sitting blood pressure: systolic pressure <90mmHg or ≥ 140mmHg, diastolic pressure ≥90mmHg or <60mmHg, which shows clinical significant abnormalities determined by investigators
  • The subjects with any biomarker value of Aspartate aminotransferase (AST),Alanine aminotransferase(ALT), Alkaline phosphatase(ALP),r-Glutamyl Transferase (r-GT), total bilirubin, creatinine above the upper limit of normal or with other clinical significant laboratory examination abnormalities judged by investigators
  • The subjects with presence of one of the following infectious diseases;
  • Virological determination indicates hepatitis B virus surface antigen (HBsAg) positive or anti-hepatitis C virus antibody positive;
  • Acquired human immunodeficiency virus determination indicates infection; (anti-human immunodeficiency virus antibody positive)
  • Treponema pallidum infection (anti-treponema pallidum-specific antibody positive).
  • Currently smoking or quitting smoking less than 3 months before screening or tobacco screening positive;
  • Chronical alcohol user within 5 years prior to screening, or alcohol consumption of more than 14 unit alcohol per week (1 unit alcohol equal to 360 mL beer, or 150 mL grape wine, or 45 mL wine of 40 degree) within 6 months prior to screening;
  • Alcohol screening test positive or alcohol intake within 72 h prior to screening;
  • Daily drinking a large amount (above 1000 mL) of tea, coffee, cola and/or caffeine-containing beverages within 6 months prior to screening;
  • Taking xanthine-containing or caffeine-containing food or beverages (including chocolate, tea, coffee and cola, etc.) from 48 hours prior to screening;
  • Taking grapefruit, lime, carambola or any food or beverages made from them within 7 days prior to screening;
  • Female subjects with blood pregnancy test positive or during lactation
  • Difficulty in blood sampling, or has relevant history, symptoms or signs of blood sampling difficulty;
  • Transfusion treatment or blood donation or massive blood loss (exceeding 450 mL) judged by investigators within 3 months prior to screening;
  • Participation in any other clinical study within 3 months prior to screening;
  • Participation in the planning or execution of this study (e.g., the sponsor or staff in the site);
  • Inappropriate to participate in this study for any reason according to the medical judgment of investigators.

Treatment and study plan

LXI-15028 50mg

Drug

In escalated single-dose study, the subjects in each dose group will receive single oral dose of 50 mg LXI-15028 tablet or 1 matching placebo tablet at fasted state,

LXI-15028 100mg

Drug

100 mg LXI-15028 tablet or matching placebo 1 tablet at fasted state, In multiple-dose study, the subjects who administered 100mg single dose will continuously receive oral 100 mg LXI-15028 tablet or 1 matching placebo tablet once daily (QD) for 10 times.

LXI-15028 200mg

Drug

single oral dose 2 100 mg LXI-15028 tablets or 2 matching placebo tablets at fasted state

Placebo

Drug

matching placebo tablets

Primary outcomes

  1. Pharmacokinetic parameter： Cmax

    Time frame: 72 h after receiving single oral dose

    The maximum plasma concentration (Cmax) after single dose LXI-15028

  2. Pharmacokinetic parameter： Tmax

    Time frame: 72 h after receiving single oral dose

    The peak time (Tmax) after single dose LXI-15028

  3. Pharmacokinetic parameter： T1/2

    Time frame: 72 h after receiving single oral dose

    The elimination half-life T1/2 after single dose LXI-15028

  4. Pharmacokinetic parameter： Kel

    Time frame: 72 h after receiving single oral dose

    The eliminate rate constant after single dose LXI-15028

  5. Pharmacokinetic parameter：Mean Residence Time(MRT)

    Time frame: 72 h after receiving single oral dose

    The mean residence time after single dose LXI-15028

  6. Pharmacokinetic parameter: Area Under plasma Concentration(AUC 0-24h)

    Time frame: 24h after receiving single oral dose

    The area under plasma concentration -time curve from 0 time ot 24 h after single dose LXI-15028

  7. Pharmacokinetic parameter: AUC 0-last

    Time frame: 72h after receiving single oral dose

    The area under plasma concentration- time curve from 0 time to sampling time of the last measurable concentration after single dose LXI-15028

  8. Pharmacokinetic parameter: AUC 0-inf

    Time frame: 72h after receiving single oral dose

    The area under plasma concentration-time curve from adminstration (0)to infinity after single dose LXI-15028

  9. Pharmacokinetic parameter: Vd/F

    Time frame: 72h after receiving single oral dose

    The apparent volume of distribution after single dose LXI-15028

  10. Pharmacokinetic parameter: Css min

    Time frame: predose at day 8, 9, and 10, 72 h after receiving last multiple oral doses

    The trough concentration at steady state(Css min) after multiple doses

  11. Pharmacokinetic parameter: Css max

    Time frame: 72 h after receiving last multiple oral doses

    The peak concentration at steady state (Css max) after multiple doses

  12. Pharmacokinetic parameter: Css av

    Time frame: 72 h after receiving last multiple oral doses

    The average concentration at steady state (Css, av)after multiple doses

  13. Pharmacokinetic parameter: Tss max

    Time frame: 72 h after receiving last multiple oral doses

    The peak time after multiple doses

  14. Pharmacokinetic parameter: Tss,1/2

    Time frame: 72 h after receiving last multiple oral doses

    The steady-state clearance half-time after multiple doses

  15. Pharmacokinetic parameter: CLss/F

    Time frame: 72 h after receiving last multiple oral doses

    Total body clearance after multiple doses

  16. Pharmacokinetic parameter: coefficient of fluctuation (DF)

    Time frame: 72 h after receiving last multiple oral doses

    coefficient of fluctuation after multiple doses

  17. Pharmacokinetic parameter: Area Under plasma Concentration at steady state (AUC ss)

    Time frame: 72 h after receiving last multiple oral doses

    The area under plasma concentration-time curve at steady state after multiple doses

  18. Pharmacokinetic parameter: Rac

    Time frame: 72 h after receiving last multiple oral doses

    The accumulation coefficient after multiple doses

  19. Physical examination value of single dose

    Time frame: Baseline to Day 4 after receiving single oral dose

    This measure is a composite. Evaluate safety and tolerability of single dose in Physical examination that should cover the head, eyes, ears, nose, throat, cardiovascular system, skin, musculoskeletal, respiratory system, digestive system, urinary system and nervous system and changes of each item from the baseline are summarized. The measurement results of each subject are summarized by different severity. All physical examination results during this trial will be listed in details.

  20. Vital signs value of single dose

    Time frame: Up to 3weeks

    The measure is a composite.Evaluate safety and tolerability of single dose in Vital signs value that including blood pressure (Systolic blood pressure/Diastolic blood pressure), pulse, body temperature，each vital sign examination values at each evaluation time point and their changes relative to the baseline will be summarized. All vital sign results should be listed. The listed vital signs are compared with normal ranges to determine whether is abnormal. The examination results that are divided into higher than normal range, normal and lower than normal range will be summarized by number of cases (n) and percentage (%). The results of abnormalities(> or < normal range) are listed.

  21. 12-lead ECG value of single dose

    Time frame: Up to 3 weeks

    Evaluate safety and tolerability of single dose in 12-lead ECG value that including ventricular rate (beats/min), PR interval (ms), QRS (ms) , QT(ms),QTc (ms)， the examination results of each ECG parameters and their changes from baseline will be summarized at each time point. Meanwhile, all 12-lead ECG examination results will be listed in details.

  22. Blood routine value of single dose

    Time frame: Baseline to Day 4 after receiving single oral dose

    Evaluate safety and tolerability of single dose in blood routine value that including White blood cells (WBC), red blood cells (RBC), hemoglobin (Hb), hematocrit (Hct), platelet, neutrophils, lymphocytes, monocytes, eosinophils, basophils, absolute neutrophil counts (ANC);and list all the result.

  23. Urine routine value of single dose

    Time frame: Baseline to Day 4 after receiving single oral dose

    Evaluate safety and tolerability of single dose in urine routine value that including specific gravity, pH, proteins, ketone,occult blood; and list all the result.

  24. Blood coagulation value of single dose

    Time frame: Baseline to Day 4 after receiving single oral dose

    Evaluate safety and tolerability of single dose in blood coagulation value that including International normalized ratio (INR), activated partial thromboplastin time (aPTT), prothrombin time (PT); and list all the result.

  25. Blood biochemistry value of single dose

    Time frame: Baseline to Day 4 after receiving single oral dose

    Evaluate safety and tolerability of single dose in blood biochemistry value that including Cholesterol, total proteins, albumin, total bilirubin, Conjugated bilirubin, creatinine, creatine kinase (CPK), alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), glutamyltransferase (γ-GT), magnesium, sodium, potassium, chlorine, total calcium, inorganic phosphorus, lactate dehydrogenase (LDH), glucose, uric acid, triglyceride (TG); and list all the result.

  26. Adverse events of single dose

    Time frame: Up to 3 weeks

    The adverse events are encoded using MedDRA 20.1. According to system organ classification (SOC) and preferred term (PT), all TEAE, investigational drug-related TEAE, Serious Adverse Event, investigational drug-related SAE, and TEAE causing premature withdrawal from this study will be separately summarized by different dose groups, including number of subjects experiencing Adverse Event, percentage and number of AE cases. The summary results are sorted according to the ranking number of cases of all subjects experiencing AE. All AE and SAE are listed by different dose groups.

  27. Physical examination value of multiple doses

    Time frame: Baseline to Day 21 after receiving the first dose

    The measure is a composite. Evaluate safety and tolerability of multiple doses in Physical examination that should cover the head, eyes, ears, nose, throat, cardiovascular system, skin, musculoskeletal, respiratory system, digestive system, urinary system and nervous system and changes of each item from the baseline are summarized. The measurement results of each subject are summarized by different severity. All physical examination results during this trial will be listed in details.

  28. Vital signs value of multiple doses

    Time frame: Baseline to Day 21 after receiving the first dose

    The measure is a composite.Evaluate safety and tolerability of multiple doses in Vital signs value that including blood pressure(Systolic blood pressure/Diastolic blood pressure), pulse, body temperature.Each vital sign examination values at each evaluation time point and their changes relative to the baseline will be summarized. All vital sign results should be listed. The listed vital signs are compared with normal ranges to determine whether is abnormal. The examination results that are divided into higher than normal range, normal and lower than normal range will be summarized by number of cases (n) and percentage (%). The results of abnormalities(> or < normal range) are listed.

  29. 12-lead ECG value of multiple doses

    Time frame: :Baseline to Day 21 after receiving the first dose

    Evaluate safety and tolerability of multiple doses in 12-lead ECG value that including ventricular rate (beats/min) ，PR interval (ms)， QRS (ms) ,，QT(ms)， QT interval (QTc )(ms). The examination results of each ECG parameters and their changes from baseline will be summarized at each time point. Meanwhile, all 12-lead ECG examination results will be listed in details.

  30. Blood routine value of multiple doses

    Time frame: Baseline to Day 21 after receiving the first dose

    Evaluate safety and tolerability of multiple doses in blood routine value that including White blood cells (WBC), red blood cells (RBC), hemoglobin (Hb), hematocrit (Hct), platelet, neutrophils, lymphocytes, monocytes, eosinophils, basophils, absolute neutrophil counts (ANC); and list all the result.

  31. Urine routine value of multiple doses

    Time frame: Baseline to Day 21 after receiving the first dose

    Evaluate safety and tolerability of multiple doses in urine routine value that including specific gravity, potential of hydrogen (pH), proteins, ketone,occult blood; and list all the result.

  32. Blood coagulation value of multiple doses

    Time frame: Baseline to Day 21 after receiving the first dose

    Evaluate safety and tolerability of multiple doses in blood coagulation value that including International normalized ratio (INR), activated partial thromboplastin time (aPTT), prothrombin time (PT);

  33. Blood biochemistry value of multiple doses

    Time frame: Baseline to Day 21 after receiving the first dose

    Evaluate safety and tolerability of multiple doses in blood biochemistry value that including Cholesterol, total proteins, albumin, total bilirubin, Conjugated bilirubin, creatinine, creatine kinase (CPK), alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), glutamyltransferase (γ-GT), magnesium, sodium, potassium, chlorine, total calcium, inorganic phosphorus, lactate dehydrogenase (LDH), glucose, uric acid, triglyceride (TG); and list all the result.

  34. Adverse events of multiple doses

    Time frame: Up to 6 weeks

    The adverse events are encoded using MedDRA 20.1. According to system organ classification (SOC) and preferred term (PT), all treatment-emergent adverse event (TEAE), investigational drug-related TEAE, serious adverse event (SAE), investigational drug-related SAE, and TEAE causing premature withdrawal from this study will be separately summarized by different dose groups, including number of subjects experiencing AE, percentage and number of adverse event (AE) cases. The summary results are sorted according to the ranking number of cases of all subjects experiencing AE. All AE and SAE are listed by different dose groups.

Secondary outcomes

  1. Pharmacokinetic parameter of major metabolite(M1): Cmax

    Time frame: 72 h after receiving single oral doses

    Major metabolite (M1) of LXI-15028 Plasma PK parameters of single doses: peak concentration Cmax

  2. Pharmacokinetic parameter of major metabolite(M1): Tmax

    Time frame: 72 h after receiving single oral doses

    Major metabolite (M1) of LXI-15028 Plasma PK parameters of single doses: peak time Tmax

  3. Pharmacokinetic parameter of major metabolite(M1): T1/2

    Time frame: 72 h after receiving single oral doses

    Major metabolite (M1) of LXI-15028 Plasma PK parameters of single doses: elimination half-life T1/2

  4. Pharmacokinetic parameter of major metabolite(M1): Kel

    Time frame: 72 h after receiving single oral dose

    Major metabolite (M1) of LXI-15028 Plasma PK parameters of single doses: eliminate rate constant

  5. Pharmacokinetic parameter of major metabolite(M1): MRT

    Time frame: 72 h after receiving single oral dose

    Major metabolite (M1) of LXI-15028 Plasma PK parameters of single doses: mean residence time

  6. Pharmacokinetic parameter of major metabolite(M1): AUC 0-24h

    Time frame: 24 h after receiving single oral dose

    Major metabolite (M1) of LXI-15028 Plasma PK parameters of single doses: area under plasma concentration-time curve from 0 time to 24 hours

  7. Pharmacokinetic parameter of major metabolite(M1): AUC 0-last

    Time frame: 72 h after receiving single oral dose

    Major metabolite (M1) of LXI-15028 Plasma PK parameters of single doses: area under plasma concentration-time curve from 0 time to the last measurable concentration

  8. Pharmacokinetic parameter of major metabolite(M1): AUC 0-inf

    Time frame: 72h after receiving single oral dose

    Major metabolite (M1) of LXI-15028 Plasma PK parameters of single doses: area under plasma concentration-time curve from 0 time to infinity

  9. Pharmacokinetic parameter of major metabolite(M1): CL/F

    Time frame: 72h after receiving single oral dose

    Major metabolite (M1) of LXI-15028 Plasma PK parameters of single dose:apparent total clearance

  10. Pharmacokinetic parameter of major metabolite(M1): Vd/F

    Time frame: 72h after receiving single oral dose

    Major metabolite (M1) of LXI-15028 Plasma PK parameters of single dose: apparent volume of distribution

  11. Pharmacokinetic parameter of major metabolite(M1): Css, min

    Time frame: :predose at day 8, 9, and 10, 72 h after receiving last multiple oral doses

    Major metabolite (M1) of LXI-15028 Plasma PK parameters of multiple doses: trough concentration at steady state

  12. Pharmacokinetic parameter of major metabolite(M1): Css, max

    Time frame: 72 h after receiving last multiple oral doses

    Major metabolite (M1) of LXI-15028 Plasma PK parameters of multiple doses:peak concentration at steady state

  13. Pharmacokinetic parameter of major metabolite(M1): Css, av

    Time frame: 72 h after receiving last multiple oral doses

    Major metabolite (M1) of LXI-15028 Plasma PK parameters of multiple doses: average concentration at steady state

  14. Pharmacokinetic parameter of major metabolite(M1): Tss, max

    Time frame: 72 h after receiving last multiple oral doses

    Major metabolite (M1) of LXI-15028 Plasma PK parameters of multiple doses: peak time

  15. Pharmacokinetic parameter of major metabolite(M1): Vss/F

    Time frame: 72 h after receiving last multiple oral doses

    Major metabolite (M1) of LXI-15028 Plasma Pharmacokinetic parameters of multiple doses:apparent volume of distribution at steady state

  16. Pharmacokinetic parameter of major metabolite(M1): tss,1/2

    Time frame: 72 h after receiving last multiple oral doses

    Major metabolite (M1) of LXI-15028 Plasma Pharmacokinetic parameters of multiple doses:steady-state clearance half-life

  17. Pharmacokinetic parameter of major metabolite(M1): CLss/F

    Time frame: 72 h after receiving last multiple oral doses

    Major metabolite (M1) of LXI-15028 Plasma Pharmacokinetic parameters of multiple doses:total body clearance

  18. Pharmacokinetic parameter of major metabolite(M1): DF

    Time frame: 72 h after receiving last multiple oral doses

    Major metabolite (M1) of LXI-15028 Plasma Pharmacokinetic parameters of multiple doses: coefficient of fluctuation

  19. Pharmacokinetic parameter of major metabolite(M1): AUCss

    Time frame: 72 h after receiving last multiple oral doses

    Major metabolite (M1) of LXI-15028 Plasma Pharmacokinetic parameters of multiple doses: area under plasma concentration-time curve at steady state

  20. Pharmacokinetic parameter of major metabolite(M1): Rac

    Time frame: 72 h after receiving last multiple oral doses

    Major metabolite (M1) of LXI-15028 Plasma PK parameters of multiple doses: accumulation coefficient

Sponsors and collaborators

Lead sponsor

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Industry

Registry information

Official study title

A Single-center, Randomized, Double-blinded and Placebo-controlled Clinical Study in Healthy Chinese Subjects to Evaluate the Pharmacokinetics, Safety and Tolerability of LXI-15028 After Receiving Escalating Single Oral Doses of LXI-15028 at 50 mg, 100 mg and 200 mg and Multiple Oral Doses of LXI-15028 at 100 mg

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Mar 8, 2018
Registry last updated
May 30, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.